How The System Helps You Succeed
What’s Included in the System
How Implementation Works
Why A Structured System Matters
Real Practice Outcomes
Creating a Profitable Practice
Patient Demand 
Patient Education 
Staff Education 
Marketing 
Regenerative Medicine Platform
Franchise & PE Support 
Wharton’s Jelly
Exosomes
Anti-Aging
Aesthetic Treatments
Neurological
Autoimmune
Wound Care
Orthopedic Conditions
Clinical Trials
Articles
Research Institutes
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a mitochondrial-derived peptide consisting of 16 amino acids.
It was first described in 2015 and is unique because it is encoded within mitochondrial DNA rather than nuclear DNA.
Research suggests MOTS-c plays an important role in regulating metabolism, insulin sensitivity, exercise capacity, and cellular stress responses.
It remains experimental and is not FDA-approved for therapeutic use.
How It Is Used in Research Settings
- Explored in metabolic research for improving insulin sensitivity and glucose regulation.
- Studied in models of obesity and type 2 diabetes for its role in reducing weight gain and improving metabolic flexibility.
- Investigated for enhancing exercise performance and endurance via mitochondrial biogenesis and AMPK activation.
- Examined in aging research for potential roles in longevity, stress resistance, and skeletal muscle health.
Proposed Uses (Research Areas)
- Metabolic disorders such as obesity, insulin resistance, and type 2 diabetes.
- Exercise physiology and performance enhancement studies.
- Aging and longevity models — potential anti-aging peptide through mitochondrial regulation.
- Cellular stress response and antioxidant defense research.
How It Is Dosed in Research Settings
- Injectable: Commonly studied at 5–15 mg subcutaneous injection, administered 2–3 times weekly in research protocols.
- Alternative dosing: Some studies evaluate daily dosing at lower levels (e.g., 2–5 mg/day) for metabolic impact.
- Cycle length: Research trials often range from 4–12 weeks depending on metabolic or performance outcomes being investigated.
- Handling: Reconstituted with bacteriostatic water, refrigerated storage recommended.
Important Considerations
- Regulatory status: MOTS-c is not FDA-approved; all current use is experimental and limited to research contexts.
- Evidence base: Most data comes from preclinical studies (rodents, cell models). Human research is very limited but emerging.
- Safety: Short-term animal studies suggest low toxicity; long-term safety in humans is not known. Purity and sourcing are critical concerns.
Disclaimer
This material is provided for educational purposes only and summarizes published research on MOTS-c.
It is not medical advice. MOTS-c is experimental, not FDA-approved, and should not be viewed as a therapy for medical use.
This peptide is for research use only.